Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Pharmacol Biochem Behav. 2018 Dec 28;177:27–33. doi: 10.1016/j.pbb.2018.12.009

Figure 1.

Figure 1.

The CB1 positive allosteric modulator ZCZ011 attenuates somatic signs of THC withdrawal. Male mice were administered THC (10 mg/kg, s.c) for 6 days and withdrawal was induced with the CB1 selective antagonist rimonabant (3 mg/kg, i.p.) 30 prior to testing. ZCZ011 (10 or 40 mg/kg, i.p.) was administered 75 min prior to final THC injection. (A,B) ZCZ011 (10 or 40 mg/kg, i.p.) reduced withdrawal-induced paw tremors and head twitches (n=8, except the vehicle/vehicle and THC/ZCZ011 40 groups, which each has n=7). Withdrawal was evaluated at 36 h after the final THC injection following a 75 min pretreatment with ZCZ011 (10 or 40 mg/kg, i.p.). (C,D) Acute ZCZ011 (10 or 40 mg/kg, i.p.) reduced paw tremors and head twitches (n=8, except the vehicle/ZCZ011 40 and THC/ZCZ011 40 groups, which each has n=7). (E) Male mice were injected with ZCZ011 (10 or 40 mg/kg, i.p.) and tested for spontaneous locomotor activity in an open chamber (n=8 per treatment). (F) In a separate group of male and female mice, ZCZ011 had no effect on conditioned place preference, but THC (5 mg/kg, i.p.) induced conditioned place aversion (n= 6M+6F per group, except the ZCZ011 10 treatment, which had n=6M+5F). Data represent mean ± SEM. *p < .05 vs. vehicle; # p<.05 vs. drug-paired side.